IMMUNIC, INC. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immunic reported Q3 2026 results with $131.96M cash (up from $15.48M at year-end 2025, funded by February 2026 private placement). Lead program vidofludimus calcium in twin Phase 3 ENSURE trials (1,121 and 1,100 relapsing MS patients enrolled) remains on schedule for December 2026 top-line data; if positive, NDA submission planned mid-2027 with potential approval in 2028. Phase 3 PROTECT-MS progressive MS trial initiating with first patient expected H1 2027. Company added Chief Data/Digital Officer (Sept 2026) and Chief People Officer (Oct 2026); board added CFO Elena Ridloff. Nine-month operating expenses reached $111.9M; net loss $109.0M ($2.83/share) on 38.5M weighted-average shares. Cash runway extends to late 2027.
Why this rating
Phase 3 readout in weeks is transformational catalyst for $83M company; December data could validate NDA pathway or destroy value. Near-term binary event materially affects trajectory.
Tradability signal
NO TRADE
No trade: positive news with only +0.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.36% over 4 hrs, n=469). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $7.67 ▼ 2.54% | at our read · unknown $7.87 | +10 min · unknown $7.71 ▼ 2.10% | +30 min · unknown $7.56 ▼ 3.94% | +1 hr · unknown $7.72 ▼ 1.91% | +4 hrs · unknown $7.70 ▼ 2.15% |
The stock had already moved +2.60% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.